Logo

American Heart Association

  29
  0


Final ID: DP34

Cardiac CT versus transesophageal and transthoracic echocardiography for intra-cardiac thrombus detection in ischemic stroke: A systematic review and meta-analysis of 43 studies

Abstract Body:
Background: Ischemic stroke, a leading cause of mortality, necessitates understanding its mechanism for effective prevention. Echocardiography is an accepted standard in stroke evaluation. Transesophageal echocardiography (TEE) being the gold standard for left atrial thrombus detection, its invasiveness, operator skill dependence, and limited availability in some centers prompt exploration of alternatives, such as cardiac computer tomography (CCT).
Objective: To provide an updated systematic review and meta-analysis assessing the ability of CCT in the detection of intracardiac thrombus as compared to echocardiography.
Methods: We searched four databases up to September 8th, 2023, adhering to PRISMA guidelines. The risk of bias was assessed using the QUADAS-2 tool and employed random-effects meta-analysis to calculate different diagnostic metrics.
Results: The meta-analysis on CCT versus echocardiography for intracardiac thrombus detection, comprising 43 studies, revealed an overall sensitivity of 98.38% (95% CI, 89.2-99.78) and specificity of 96.0% (95% CI, 92.55-97.88). Subgroup analyses demonstrated that delayed phase, electrocardiogram gated CCT had the highest sensitivity (100%; 95% CI, 0-100), while early phase, non-gated CCT exhibited a sensitivity of 94.31% (95% CI, 28.58-99.85). The diagnostic odds ratio was 98.59 (95% CI, 44.05-220.69). Heterogeneity was observed, particularly in specificity and diagnostic odds ratios estimates.
Conclusions: CCT demonstrates high sensitivity, specificity, and diagnostic odds ratios in detecting intracardiac thrombus compared to traditional echocardiography. Large scale studies are warranted to further evaluateCCT as a promising alternative for identifying intracardiac thrombus.
  • Ghozy, Sherief  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Liu, Michael  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Kobeissi, Hassan  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Abbas, Alzhraa S.  ( MAYO CLINIC , Rochester , Minnesota , United States )
  • Kadirvel, Ram  ( MAYO CLINIC , Rochester , Minnesota , United States )
  • Rabinstein, Alejandro  ( MAYO CLINIC NEUROLOGY , Rochester , Minnesota , United States )
  • Kallmes, David  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Nasr, Deena  ( MAYO CLINIC , Rochester , Minnesota , United States )
  • Author Disclosures:
    Sherief Ghozy: DO NOT have relevant financial relationships | Michael Liu: DO NOT have relevant financial relationships | Hassan Kobeissi: No Answer | Alzhraa S. Abbas: No Answer | Ram Kadirvel: DO have relevant financial relationships ; Research Funding (PI or named investigator):NIH:Active (exists now) ; Other (please indicate in the box next to the company name):Rion Inc:Active (exists now) ; Research Funding (PI or named investigator):Medical Device Innovation:Active (exists now) ; Research Funding (PI or named investigator):Stryker:Past (completed) ; Research Funding (PI or named investigator):Sensome:Past (completed) ; Research Funding (PI or named investigator):Cerenovus:Active (exists now) ; Research Funding (PI or named investigator):Piraeus Medical:Active (exists now) ; Other (please indicate in the box next to the company name):Metronic:Active (exists now) ; Research Funding (PI or named investigator):Octapharma:Active (exists now) ; Research Funding (PI or named investigator):Bionaut Labs:Active (exists now) | Alejandro Rabinstein: DO have relevant financial relationships ; Advisor:Chiesi:Past (completed) ; Other (please indicate in the box next to the company name):Boehringer Ingelheim (CEC member):Active (exists now) ; Other (please indicate in the box next to the company name):Boston Scientific (CEC member):Active (exists now) ; Advisor:Shionogi:Active (exists now) ; Advisor:Ceribell:Past (completed) | David Kallmes: DO have relevant financial relationships ; Individual Stocks/Stock Options:Piraeus Medical:Active (exists now) ; Research Funding (PI or named investigator):Stryker:Past (completed) ; Research Funding (PI or named investigator):Medical Device Engineering:Active (exists now) ; Research Funding (PI or named investigator):Octapharma:Active (exists now) ; Research Funding (PI or named investigator):Sensome:Active (exists now) ; Research Funding (PI or named investigator):Cerenovus:Active (exists now) ; Ownership Interest:Superior Medical Editors:Active (exists now) ; Individual Stocks/Stock Options:Nested Knowledge:Active (exists now) ; Ownership Interest:Conway Medical:Active (exists now) | Deena Nasr: DO NOT have relevant financial relationships
Meeting Info:
Session Info:

Imaging Moderated Digital Posters

Thursday, 02/06/2025 , 12:40PM - 01:10PM

Moderated Digital Poster Abstract Session

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)